LearnGlossaryMarketStocksSuperinvestorsSign in

SNDX

Syndax Pharmaceuticals, Inc.

Healthcare · $1.8B market cap

Verdict

We can't put a fair value on SNDX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth1.3% a year✗
Sales growth5.4% a year✗
Free cash flow growth—?
Return on invested capital-53.9%✗

Follow SNDX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds SNDX. In Q2 2026, 1 added. Who we track

Torray Funds

Torray Funds · as of Q2 2026

$2.9M

133,835 shares

Moves in Q2 2026

Added: Torray Funds

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML)…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works